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PODIUM SESSION IV: INFECTION
IN1
COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR/R FOR HIV
INFECTION IN TREATMENT-EXPERIENCED ADULTS IN THE
US: UNDERSTANDING THE UNCERTAINTY IN THE ESTIMATES
Brogan A1, Mauskopf J1, Martin SC2, Smets E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson &
Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, 3Johnson &
Johnson Pharmaceutical Services, Inc, Beerse, Belgium
OBJECTIVES: Cost-effectiveness estimates for new drugs are
generally derived from limited data on product efﬁcacy and likely
treatment patterns. We evaluated the base-case cost-effectiveness,
from a US perspective, of ritonavir-boosted darunavir
(TMC114/r; darunavir/r), a novel protease inhibitor, plus an
optimized background regimen (OBR) compared with currently
available protease inhibitors plus OBR, for treating HIV infec-
tion in treatment-experienced adults. We then subjected these
estimates to sensitivity and variability analyses, to assess the
effects of uncertainty in the base-case estimates. METHODS: A
Markov model with 3-month cycles was developed to follow
patients through six health states deﬁned by CD4+ cell-count
ranges. Transition probabilities were calculated from clinical
trial data. Cost (2005 US dollars), utility, and mortality data
were estimated from published US sources. The 5-year incre-
mental cost-effectiveness ratio (ICER) was calculated for the base
case. The base case was tested with one-way and probabilistic
sensitivity analyses (PSA) as well as for alternative practice pat-
terns, population and model characteristics (variability analyses).
RESULTS: The base-case 5-year ICER for darunavir/r was
$4657/QALY. The one-way sensitivity analysis results ranged
from −$12,086/QALY (darunavir/r is dominant) to
+$24,899/QALY. Results were most sensitive to uncertainty
about durations of CD4+ increase and stability, rates of CD4+
change, and non-antiretroviral health care costs. By PSA, the
probability of the ICER being below the commonly accepted
threshold of $50,000/QALY was 95.5%. The variability analy-
sis resulted in ICERs between −$42,029 (darunavir/r is domi-
nant) and +$33,625. The lower bound occurred when tipranavir
was the assumed comparator, while the upper bound occurred
when the model time horizon was extended to lifetime. CON-
CLUSION: The impact of parameter uncertainty assessed by sen-
sitivity analysis on the estimated ICER was less than the impact
of variability. Each type of analysis contributes to a fuller under-
standing of the uncertainty in base-case cost-effectiveness 
estimates. After analyses of uncertainty, darunavir/r remains
cost-effective.
IN2
MARKET STRUCTURE AND EFFECTIVENESS OF PRICE
CONTROL FOR ANTIRETROVIRAL MEDICAMENTS IN
COLOMBIA
Garavito L1, Ruiz F2
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OBJECTIVES: Medicament prices restrict the population access
to antiretroviral therapy in developing countries. International
comparisons indicate Colombia is paying higher ARV prices than
comparative developing countries. In addition, its health system
is highly decentralized due to the large number of institutional
buyers. This study addresses the effectiveness of the price control
regulatory strategy to lower ARV prices and access to therapy.
METHODS: A cross sectional study was performed through a
survey designed for the universe of institutional ARV buyers
(2005). This included insurers and hospitals linked to the Colom-
bian Health and Social Security System. The survey asked infor-
mation about VIH/AIDS infected population, individual ARV
medicaments transactions, prices, discounts and procurement
processes. Descriptive statistics and a multivariate economic
model were performed. The answer rate covered over 87% of
Colombian population. RESULTS: Study results accounted up to
20,697 persons HIV infected. A 79.8% treatment rate was
obtained. Signiﬁcant differences in the infection rate between
both social insurance schemes were identiﬁed: Contributive
insurance population had a 2.7 higher infection probability than
those in the subsidized plan. The lineal regression model showed
no signiﬁcant relationship between the size of the insurance pool
and antiretroviral ﬁnal price to the buyer. Also, there were no
price differences between direct purchases to manufacturers and
those to distributors. There was a monopolistic tendency with
45% of medicaments offered by a single manufacturer. A market
concentration index (Hirsmann-Herﬁndahl) show that 55% of
medicaments purchased in oligopolistic settings. There were no
signiﬁcant price differences from brand-name medicaments and
generic drugs in 12 up to 14 ARV medicaments. Finally, there
were no signiﬁcant relation between the regulated price and
actual institutional prices. CONCLUSION: Colombia should
diversify its regulatory mechanisms and incentives to assure com-
petitiveness, and scale economies in antiretroviral purchases.
This approach should face prospective strategies to compensate
institutional market fragmentation.
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FINDINGS FROM A NATIONAL DATABASE
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1Boston Health Economics, Inc, Waltham, MA, USA, 2Pﬁzer Global
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OBJECTIVES: Patients receiving mechanical ventilation are at
an increased risk of pneumonia, which can prolong hospital stays
and increase costs. There are limited national data on the costs
of ventilator-associated pneumonia (VAP) due to Staphylococcus
aureus, a common hospital-acquired pathogen. METHODS:
This retrospective cohort study used data from the 2004 Health
care Cost and Utilization Project Nationwide Inpatient Sample
(HCUP-NIS). Ventilator-dependent patients with S. aureus pneu-
monia were identiﬁed based on ICD-9-CM diagnosis and pro-
cedure codes and compared to ventilator-dependent patients
without a diagnosis of pneumonia. Excess length of stay (LOS)
and costs were estimated. Multivariate models were used to
adjust costs for potential confounding factors, including age,
gender, mortality, hospital region, and comorbidity. RESULTS:
We identiﬁed 198,269 hospitalized patients who required use of
a ventilator, of whom 9592 (4.8%) were identiﬁed as having S.
aureus pneumonia. Patients with VAP due to S. aureus were older
(mean age 62 years vs. 49 years for the comparison group) and
were more likely to have congestive heart failure, chronic pul-
monary disease, diabetes and bacteremia/septicemia. Relative to
the comparison group, patients with VAP due to S. aureus had
signiﬁcantly (P < 0.001) longer mean length of stay (25.6 vs. 14.5
days) and substantially higher average costs per stay ($72,820
vs. $40,171). After controlling for potentially confounding
factors, the excess costs associated with VAP due to S. aureus
were estimated to be approximately $14,000. CONCLUSION:
Our ﬁndings suggest that the economic burden of ventilator-
associated pneumonia (VAP) due to Staphylococcus aureus
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among hospitalized patients is substantial. Further research is
needed to assess the value of large hospital discharge databases
for documenting and distinguishing the costs of speciﬁc bacter-
ial pathogens.
IN4
ECONOMIC EVALUATION OF INFLUENZA PANDEMIC
MITIGATION STRATEGIES IN THE US USING A STOCHASTIC
MICROSIMULATION INFLUENZA MODEL
Sander B1, Nizam A2, Garrison LP3, Postma MJ4, Halloran ME3,
Longini Jr IM3
1University of Toronto,Toronto, ON, Canada, 2Emory University,
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OBJECTIVES: To project the potential impact of pandemic
inﬂuenza mitigation strategies on health outcome, cost, and cost-
effectiveness from a societal perspective. METHODS: We use a
stochastic agent-based model to simulate pandemic inﬂuenza in
the community. We compare 16 strategies to no intervention,
focusing on targeted antiviral prophylaxis (TAP) with
oseltamivir (treatment of identiﬁed index cases and prophylaxis
of exposed people) alone and in combination with school
closure. We also consider pre-vaccination of the population. We
use the human capital approach to estimate productivity loss.
Outcomes include number of cases, deaths, QALYs, direct and
indirect costs, and incremental cost-effectiveness ratios (ICERs)
expressed as costs per QALY gained. RESULTS: In the absence
of intervention, we predict a 50% attack rate with an economic
impact of $187 per capita. TAP + school closure and pre-vacci-
nation + school closure (preventing 94–96% of cases at $2730
per capita)) are comparable in terms of QALY gain and total
costs. The ICER compared to TAP alone (the most effective
single strategy) is about $50,500/QALY for either strategy. The
most effective single strategy is TAP alone (prophylaxis of 60%
of close contacts of index cases) which effectively prevents 54%
of cases at a cost of $120 per capita. If vaccine is available and
administered before the onset of the pandemic, then pre-vacci-
nating 70% of the population with a partially effective vaccine
prevents 48% of cases and is the least costly alternative ($99 per
capita), dominating all but one TAP only strategies, treatment
and school closure. Sensitivity analysis on key variables does not
change the ranking of strategies but shows that mortality has the
greatest impact on QALYs and hence ICERs. CONCLUSION:
Targeted antiviral prophylaxis is an effective and cost-saving
measure for mitigating pandemic inﬂuenza. Adding school
closure provides greater beneﬁt and is likely to be an attractive
strategy if mortality is high.
PODIUM SESSION IV: OBESITY
OB1
IMPACT OF OBESITY SEVERITY ON HEALTH CONDITIONS
AND MEDICAL COSTS IN THE US
Liu G1,Tian H2, Zhao Z3, Le TK3
1Peking University, Beijing, China, 2RAND Corporation, Santa Monica,
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OBJECTIVES: To assess the impact of severity of obesity on
medical comorbidities, perceived health status and medical costs
in the US. METHODS: This study analyzed the 2004 Medical
Expenditure Panel Survey (MEPS). Based on the Body Mass
Index (BMI), weight groups were deﬁned as Underweight (UW,
BMI < 18.5), Normal Weight (NW, BMI 18.5–24.9), Overweight
(OW, BMI 25–29.9), Obese I (BMI 30–34.9), Obese II (BMI
35–39.9), and Obese III (BMI >= 40). Multiple logistic regres-
sions were modeled to estimate the impact of severity of obesity
on medical comorbidities and perceived health status. Two part
models (TPMs) were employed to estimate the cost functions
controlling for socio-demographic characteristics and physical
health conditions. All estimates are weighted to be nationally
representative and the costs are adjusted for the Smearing effect.
RESULTS: In the nationally representative sample (mean age
45.5 years; 51.4% female), 2.1% were UW, 37.0% NW, 35.1%
OW, 16.4% obese I, 6.1% obese II and 3.4% obese III. Com-
pared to NW, obese I, II and III were more likely to have dia-
betes (odds ratio (OR) = 3.5, 5.7, and 10.8, p < 0.001), asthma
(OR = 1.4, 2.1, and 2.6, p < 0.001), and joint pain (OR = 1.7,
2.2 and 2.9, p < 0.001), and reported signiﬁcantly poorer per-
ceived health status (OR = 0.6, 0.4 and 0.3, p < 0.001), respec-
tively. The TPMs results showed that compared to NW patients,
obese II and III were more likely to incur higher costs (OR = 1.3,
and 1.4, p < 0.05), and patients from obese I, II and II also had
signiﬁcantly higher costs compared to NW patients ($4643,
$5000, $4811 vs. $3999, p < 0.001). CONCLUSION: Obesity
is a major public health concern and has a large economic impact
to the US population. The severity of obesity is signiﬁcantly asso-
ciated with increased medical comorbidities, decreased health
status and high medical costs.
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THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY:
FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY
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OBJECTIVES: The cardiovascular consequences of the meta-
bolic syndrome and its component risk factors (i.e., abdominal
obesity, low HDL cholesterol or elevated triglyercides, hyper-
tension, elevated blood glucose) have been documented in the
elderly. To date, little is known about how the metabolic syn-
drome and its components translate into long-term medical
costs. METHODS: We used clinical data and matching, longi-
tudinal Medicare claims from 3789 individuals aged 65 years
and older in the Cardiovascular Health Study followed up to 10
years. The metabolic syndrome was deﬁned according to the
National Cholesterol Education Program’s Third Adult Treat-
ment Panel Report (NCEP-ATP III) criteria. W calculated costs
by summing Medicare payment amounts for each participant,
and discounted costs at 3% annually. Log-linear regression
models were used to assess the independent contributions of the
metabolic syndrome and its component risk factors to 10-year
medical costs among. RESULTS: As deﬁned by the NCEP ATP
III criteria, the metabolic syndrome was present in 47% of the
sample. Total per patient costs to Medicare were 20% higher
among those with the metabolic syndrome ($40,827 vs. $32,962,
p < 0.001). Controlling for age, gender, race and other covari-
ates, abdominal obesity, low HDL cholesterol, and elevated
blood pressure were associated with 15% (95% conﬁdence inter-
val [CI] 4.3%–26.7%), 16% (CI: 1.1%–31.8%), and 20% (CI
10.1%–31.7%) higher total costs, respectively. When added to
the model, the metabolic syndrome composite variable did not
contribute signiﬁcantly (p = 0.32). CONCLUSION: Abdominal
obesity, low HDL cholesterol, and hypertension, but not the
metabolic syndrome, are important predictors of long-term costs
in the Medicare population. The combined effects of abdominal
obesity, low HDL cholesterol, and elevated blood pressure are
associated with 50% higher Medicare costs.
